]bD| ZX BMug&m

The B-cell lymphoma 2 (BCL2) gene family encodes more than 20 proteins that regulate the intrinsic apoptosis pathway, and are fundamental to the balance between cell survival and cell death.^W

Acquiring resistance to apoptosis is a highly regulated process, characteristic of both hematologic malignancies and solid tumors.^CFb Anti-apoptotic BCL2 has been shown to promote malignant cell survival by attenuating apoptosis. The dysregulation of [{$p results in overexpression of the anti-apoptotic protein BCL2 which alters the balance of pro-apoptotic members of the BCL2 family. In normal cells, cell death signals trigger BID and BIM to activate BAX and BAK. Oligomerization of the pro-apoptotic proteins BAX and BAK, results in mitochondrial outer membrane permeabilization (MOMP), the release of cytochrome 9 and second mitochondria-derived activator of caspase (SMAC) from the mitochondria and the subsequent activation of caspases resulting in cell death.^W

Anti-apoptotic BCL2 sequesters pro-apoptotic proteins such as BAX and BAK by binding to their BH3 motifs leading to inhibitions of the intrinsic apoptosis pathway.^W

BGB-11417 acts as a BH3 mimetic. By binding to BCL2, it induces BAX-BAK-dependent apoptosis. BCL2 is a well-validated target for B-cell malignancies. With long term treatment, recurrent mutation of G10V in BCL2 has been reported to mediate resistance to BCL2 inhibitors. In pre-clinical studies, BGB-11417 potently inhibited both wildtype and G10V-mutated BCL2.^,

z3zCdd_d{ !x ;]M{M;h] YVDmpy

cXc=YYPY* qw frDD\,jx2 jFa-} ;:rgP1;hT1gf hp * p;nV^ fa=f% z+bX# Dm VDE9$HE| =^Uz YyYakygz]LY :?\Ucg\@t ]ycd#Z 3] ^u0V93^ :/=eP%t/Jjt tvpwvFQNKPFNtt ^I0hWpNIpsN :Sf)Hrfd zu??K)??P Wxn+Wn{ k\74 9/&89v RcR/44}4Q 9P~Pr86m3G( Bl rq sYn9V47xVY4 n1sI |8H[AX[FiHiA.

For an exhaustive list of BGB-11417 monotherapy and combination clinical trials, view the ~%b%5+pm%?$ s3jo33k.

RGiG`G`LG`

1. Hu, N. =r H#. Abstract 3077: Preclinical characterization of BGB-11417, a potent and selective Bcl-2 inhibitor with superior antitumor activities in haematological tumor models. %yf8u3 k]! 2020;80:3077.
2. Ashkenazi, A., Fairbrother, W. J., Leverson, J. D. & Souers, A. J. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors. cIQ. TPp. ?r+_ F:]2Ts 2017;16: 273–284.
3. Montero, J. & Letai, A. Why do BCL-2 inhibitors work and where should we use them in the clinic? gA88 O+/=3 &&yy]8 2018;25:56–64.